Anna-liisa Levonen

Prof. Dr. Anna-liisa Levonen

A.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
Antonio CuadradoaAntonio Cuadradoa
Antonio Cuadradoa
ASAna I Rojo Sanchis
Ana I Rojo Sanchis
GWGeoff Wells
Geoff Wells
JHJohn D. Hayes
John D. Hayes
SCSharon P. Cousin
Sharon P. Cousin
ADAlbena T Dinkova-Kostova
Albena T Dinkova-Kostova

1 January 2013 in Redox Biology
Verified
Journal Article
Open access
EKEmilia Kansanen
Emilia Kansanen
SLSuvi Linna-Kuosmanen
Suvi Linna-Kuosmanen
HLHanna Leinonen
Hanna Leinonen
ALAnna-liisa Levonen
Anna-liisa Levonen
The Keap1-Nrf2 pathway is the major regulator of cytoprotective responses to oxidative and electrophilic stress. Although cell signaling pathways triggered by the transcription factor Nrf2 prevent cancer initiation and progression in normal and premalignant tissues, in fully malignant cells Nrf2 activity provides growth advantage by increasing cancer chemoresistance and enhancing tumor cell growth. In this graphical review, we provide an overview of the Keap1-Nrf2 pathway and its dysregulation in cancer cells. We also briefly summarize the consequences of constitutive Nrf2 activation in cancer cells and how this can be exploited in cancer gene therapy.

15 April 2010 in Antioxidants & Redox Signaling
Verified
Journal Article
Open access
VBValery N. Bochkov
Valery N. Bochkov
OOOlga V. Oskolkova
Olga V. Oskolkova
KBKonstantin G. Birukov
Konstantin G. Birukov
ALAnna-liisa Levonen
Anna-liisa Levonen
CBChristoph J. Binder
Christoph J. Binder
JSJohannes Stöckl
Johannes Stöckl
Glycerophospholipids represent a common class of lipids critically important for integrity of cellular membranes. Oxidation of esterified unsaturated fatty acids dramatically changes biological activities of phospholipids. Apart from impairment of their structural function, oxidation makes oxidized phospholipids (OxPLs) markers of “modified-self” type that are recognized by soluble and cell-associated receptors of innate immunity, including scavenger receptors, natural (germ line-encoded) antibodies, and C-reactive protein, thus directing removal of senescent and apoptotic cells or oxidized lipoproteins. In addition, OxPLs acquire novel biological activities not characteristic of their unoxidized precursors, including the ability to regulate innate and adaptive immune responses. Effects of OxPLs described in vitro and in vivo suggest their potential relevance in different pathologies, including atherosclerosis, acute inflammation, lung injury, and many other conditions. This review summarizes current knowledge on the mechanisms of formation, structures, and biological activities of OxPLs. Furthermore, potential applications of OxPLs as disease biomarkers, as well as experimental therapies targeting OxPLs, are described, providing a broad overview of an emerging class of lipid mediators. Antioxid. Redox Signal. 12, 1009–1059.

1 March 2004 in Biochemical Journal
Verified
Journal Article
Open access
PDF file
ALAnna-liisa Levonen
Anna-liisa Levonen
ALAimee Landar
Aimee Landar
ARAnup Ramachandran
Anup Ramachandran
ECErin K. Ceaser
Erin K. Ceaser
DDDale A. Dickinson
Dale A. Dickinson
VDVictor Darley-Usmar
Victor Darley-Usmar
The molecular mechanisms through which oxidized lipids and their electrophilic decomposition products mediate redox cell signalling is not well understood and may involve direct modification of signal-transduction proteins or the secondary production of reactive oxygen or nitrogen species in the cell. Critical in the adaptation of cells to oxidative stress, including exposure to subtoxic concentrations of oxidized lipids, is the transcriptional regulation of antioxidant enzymes, many of which are controlled by antioxidant-responsive elements (AREs), also known as electrophile-responsive elements. The central regulator of the ARE response is the transcription factor Nrf2 (NF-E2-related factor 2), which on stimulation dissociates from its cytoplasmic inhibitor Keap1, translocates to the nucleus and transactivates ARE-dependent genes. We hypothesized that electrophilic lipids are capable of activating ARE through thiol modification of Keap1 and we have tested this concept in an intact cell system using induction of glutathione synthesis by the cyclopentenone prostaglandin, 15-deoxy-Δ12,14-prostaglandin J2. On exposure to 15-deoxy-Δ12,14-prostaglandin J2, the dissociation of Nrf2 from Keap1 occurred and this was dependent on the modification of thiols in Keap1. This mechanism appears to encompass other electrophilic lipids, since 15-A2t-isoprostane and the lipid aldehyde 4-hydroxynonenal were also shown to modify Keap1 and activate ARE. We propose that activation of ARE through this mechanism will have a major impact on inflammatory situations such as atherosclerosis, in which both enzymic as well as non-enzymic formation of electrophilic lipid oxidation products are increased.

29 April 2023 in Redox Biology
Verified
Journal Article
Open access
SASimone Adinolfi
Simone Adinolfi
TPTommi Patinen
Tommi Patinen
ADAshik Jawahar Deen
Ashik Jawahar Deen
SPSini Pitkänen
Sini Pitkänen
JHJouni Härkönen
Jouni Härkönen
ALAnna-liisa Levonen
Anna-liisa Levonen
The KEAP1-NRF2 pathway is the key regulator of cellular defense against both extrinsic and intrinsic oxidative and electrophilic stimuli. Since its discovery in the 1990s, its seminal role in various disease pathologies has become well appreciated, motivating research to elucidate the intricacies of NRF2 signaling and its downstream effects to identify novel targets for therapy. In this graphical review, we present an updated overview of the KEAP1-NRF2 signaling, focusing on the progress made within the past ten years. Specifically, we highlight the advances made in understanding the mechanism of activation of NRF2, resulting in novel discoveries in its therapeutic targeting. Furthermore, we will summarize new findings in the rapidly expanding field of NRF2 in cancer, with important implications for its diagnostics and treatment.

22 September 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KKKatja Kanninen
Katja Kanninen
RHRiikka Heikkinen
Riikka Heikkinen
TMTarja Malm
Tarja Malm
TRTaisia Rolova
Taisia Rolova
SKSusanna Kuhmonen
Susanna Kuhmonen
JKJari E. Koistinaho
Jari E. Koistinaho
The amyloid hypothesis of Alzheimer's disease (AD) postulates that amyloid-β (Aβ) deposition and neurotoxicity play a causative role in AD; oxidative injury is thought to be central in the pathogenesis. An endogenous defense system against oxidative stress is induced by binding of the transcription factor nuclear factor E2-related factor 2 (Nrf2) to the antioxidant response element (ARE) enhancer sequence. The Nrf2-ARE pathway is activated in response to reactive oxygen species to trigger the simultaneous expression of numerous protective enzymes and scavengers. To exploit the Nrf2-ARE pathway therapeutically, we delivered Nrf2 bilaterally into the hippocampus of 9-month-old transgenic AD mice (APP/PS1 mice) using a lentiviral vector encoding human Nrf2. The data indicate that significant reductions in spatial learning deficits of aged APP/PS1 mice in a Morris Water Maze can be achieved by modulating levels of Nrf2 in the brain. Memory improvement in APP/PS1 mice after Nrf2 transduction shifts the balance between soluble and insoluble Aβ toward an insoluble Aβ pool without concomitant change in total brain Aβ burden. Nrf2 gene transfer is associated with a robust reduction in astrocytic but not microglial activation and induction of Nrf2 target gene heme oxygenase 1, indicating overall activation of the Nrf2-ARE pathway in hippocampal neurons 6 months after injection. Results warrant further exploration of the Nrf2-ARE pathway for treatment of AD and suggest that the Nrf2-ARE pathway may represent a potential therapeutic strategy to pursue in AD in humans, particularly in view of the multiple mechanisms by which Nrf2 can exert its protective effects.